Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.

Chernock RD, Hagemann IS.

Am J Clin Pathol. 2015 Jun;143(6):768-77. doi: 10.1309/AJCPHWACTTUYJ7DD. Review.

PMID:
25972318
2.

Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F.

J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22.

PMID:
8636377
3.

RAS proto-oncogene in medullary thyroid carcinoma.

Moura MM, Cavaco BM, Leite V.

Endocr Relat Cancer. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070. Review.

PMID:
26285815
4.

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG.

Cancer Res. 1996 Mar 15;56(6):1241-3.

5.

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A.

J Clin Endocrinol Metab. 2007 Dec;92(12):4725-9. Epub 2007 Sep 25.

PMID:
17895320
7.

Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.

Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.

Cancer. 1995 Aug 1;76(3):479-89.

PMID:
8625130
8.

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM, Lacroix L.

J Clin Endocrinol Metab. 2012 Oct;97(10):E2031-5. doi: 10.1210/jc.2012-2092. Epub 2012 Aug 3.

9.
10.

Management of hereditary medullary thyroid carcinoma.

Pappa T, Alevizaki M.

Endocrine. 2016 Jul;53(1):7-17. doi: 10.1007/s12020-016-0873-1. Epub 2016 Feb 2. Review.

PMID:
26839093
11.

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

Moura MM, Cavaco BM, Pinto AE, Leite V.

J Clin Endocrinol Metab. 2011 May;96(5):E863-8. doi: 10.1210/jc.2010-1921. Epub 2011 Feb 16.

PMID:
21325462
12.

Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.

Fugazzola L, Cerutti N, Mannavola D, Ghilardi G, Alberti L, Romoli R, Beck-Peccoz P.

Clin Endocrinol (Oxf). 2002 Jan;56(1):53-63. Erratum in: Clin Endocrinol (Oxf) 2002 Apr;56(4):563.

PMID:
11849247
13.

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.

Am J Pathol. 2004 Aug;165(2):511-21.

14.

Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.

Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA.

Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7.

PMID:
7641404
15.

Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M.

Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3330-5.

16.

Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.

Ruiz A, Antiñolo G, Fernández RM, Eng C, Marcos I, Borrego S.

Clin Endocrinol (Oxf). 2001 Sep;55(3):399-402.

PMID:
11589684
17.

Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.

Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V.

Mol Cell Endocrinol. 1998 Feb;137(1):51-7.

PMID:
9607728
19.

Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.

Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y.

J Hum Genet. 1998;43(2):101-6.

PMID:
9621513
20.

Management of medullary thyroid carcinoma.

Jiménez C, Hu MI, Gagel RF.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):481-96, x-xi. doi: 10.1016/j.ecl.2008.03.001. Review.

PMID:
18502338

Supplemental Content

Support Center